Zymeworks

ZYMEWORKS INC

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Biotech

Earnings

Equities

News

Health Care

Movers

Trading Ideas

General

JAZZ

ZYME

Zymeworks shifts focus to ZW251 for liver cancer, delaying ZW220. Q4 revenue and earnings missed estimates. GSK milestone adds $14M to cash reserves.

Cancer-Focused Zymeworks&#39; Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251


Zymeworks (NYSE:ZYME) came into focus in late December when major shareholder EcoR1 Capital increased its stake. Already a 10% holder and board member, EcoR1 made several purchases in December and the first days of

Zymeworks in Focus for Insider Activity: Catalysts Ahead

Zymeworks Inc

Management

Press Releases

Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors

Zymeworks Announces Participation in Upcoming Investor Conferences

Financing

Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting

Zymeworks to Report First Quarter 2025 Financial Results and  Host Conference Call on May 8, 2025

Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results

Akebia Therapeutics

Ardelyx

ArriVent BioPharma

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

Bicara Therapeutics

CareDx

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

89bio

Geron

Gyre Therapeutics

Immunome

MiMedx Group

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

Nurix Therapeutics

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Novavax

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Arcus Biosciences

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

Spyre Therapeutics

Vir Biotechnology

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

LifeSci Capital

HC Wainwright & Co.

Citigroup

Wells Fargo

JP Morgan

Zymeworks BC

Comments

Zymeworks

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell